FcGR3A (CD16A) CHO Cell Line
Recombinant CHO cell line stably expressing full length human CD16A (also known as FCGR3A, FcγRIIIa; ref. seq. NM_ 000569.8) under the control of the CMV promoter.
Purchase of this cell line is for research purposes only; commercial use requires a separate license. View the full terms and conditions.
Name | Ordering Information |
Thaw Medium 3 | BPS Bioscience #60186 |
Growth Medium 3J | BPS Bioscience #79974 |
For best results, it is highly recommended to use these validated and optimized media from BPS Bioscience. Other preparations or formulations of media may result in suboptimal performance.
Thaw Medium 3 (BPS Bioscience #60186):
F-12K Medium (Kaighn's Modification of Ham's F-12 Medium) supplemented with 10% FBS, 1% Penicillin/Streptomycin
Growth Medium 3J (BPS Bioscience #79974):
F-12K Medium (Kaighn's Modification of Ham's F-12 Medium) supplemented with 10% FBS, 1% Penicillin/Streptomycin plus 5 μg/ml of Puromycin
The cell line has been screened to confirm the absence of Mycoplasma species.
Fc Gamma Receptor 3A (FcGRIIIA; FcγRIIIA), also known as CD16A, is a low/intermediate affinity receptor for polyvalent immune-complexed IgG. It is involved in phagocytosis, antibody-dependent cytotoxicity, and clearance of immune complexes. The human FcGR3A displays a dimorphism at residue 158. One allele (V158) encodes a higher Fc affinity receptor variant with a valine at amino acid residue 158 while the other allele (F158) encodes a lower Fc affinity receptor variant having a phenylalanine at amino acid residue 158.
FcGR3A (CD16A) plays a role in the activation of natural killer (NK) cells. Clinically, it serves as a marker of certain immune cells such as neutrophils. Its expression has been observed at the surface of T cells in patients with chronic viral infections (such as COVID-19). It is considered a potential therapeutic target to potentiate the efficacy of therapeutic antibodies used to treat solid tumors, or as direct target in hematopoietic cancers.